Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
Haratani K, Nakamura A, Mamesaya N, Sawa K, Shiraishi Y, Saito R, Tanizaki J, Tamura Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Tokito T, Nagata K, Masuda T, Nakamura Y, Sakai K, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H.
Haratani K, et al. Among authors: tamura y.
Br J Cancer. 2024 May;130(11):1783-1794. doi: 10.1038/s41416-024-02662-2. Epub 2024 Mar 22.
Br J Cancer. 2024.
PMID: 38519705